DA
SCMP

Denali Advisors’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Denali Advisors’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-9,800
Closed -$169K – 321
2015
Q4 		$169K Sell
9,800
-4,300
-30% -$77.1K 0.04% 126
2015
Q3 		$280K Buy
+14,100
New +$323K 0.06% 121

Other funds holding SCMP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Denali Advisors's SCMP Position: Q1 2016 in Review

Denali Advisors sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2016, closing a stake of 9,800 shares — an estimated $169K sold.

Denali Advisors first reported a position in SCMP in Q3 2015 and held it in 2 quarters. The position peaked at $280K in Q3 2015. 134 funds tracked by Wall St. Rank hold SCMP as of Q1 2016.

  • Denali Advisors reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Denali Advisors sold 9,800 Sucampo Pharmaceuticals, Inc. shares in Q1 2016, an estimated $169K.
  • Denali Advisors first reported a position in Sucampo Pharmaceuticals, Inc. in Q3 2015 and held it in 2 quarters.
  • Denali Advisors's Sucampo Pharmaceuticals, Inc. position peaked at $280K in Q3 2015.
  • 134 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2016.

Based on Denali Advisors's 13F filing for Q1 2016, filed 11 Apr 2016.